선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
The Estee Lauder Companies Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $33.3B | |
|---|---|---|
| Revenue (ttm) | 15B | |
| Net income (ttm) | 182M | |
| EPS (ttm) | $0.50 | |
| Shares out | 361.8M | |
| P/E (trailing) | 218.4x | |
| P/E (forward) | 29.8x | |
| Dividend | $1.40 (1.28%) | |
| Volume | 2,423,779 | |
| Beta | 1.27 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2026-06-30 | Trend |
| Revenue | $17.74B | $15.91B | $15.61B | $14.33B | $15.05B | -4.0% |
| Gross profit | $13.43B | $11.35B | $11.18B | $10.60B | $11.36B | -4.1% |
| Operating income | $3.17B | $1.51B | $970.0M | $-785.0M | $780.0M | -29.6% |
| Net income | $2.39B | $1.01B | $390.0M | $-1.13B | $182.0M | -47.5% |
| EPS (diluted) | $6.55 | $2.79 | $1.08 | $-3.15 | $0.50 | -47.4% |
| EBITDA | $3.93B | $2.40B | $1.98B | $146.0M | $1.65B | -19.5% |
| R&D | $307.0M | $344.0M | $360.0M | $316.0M | — | +1.0% |
| SG&A | $9.89B | $9.58B | $9.62B | $9.46B | $9.69B | -0.5% |
Recent company headlines from major financial publishers.
The modal expected path reflects gradual operational recovery under the Profit Recovery and Growth Plan, with FY2027 net sales growing 4.46% to $15,720M and FY2028 revenue expanding 4.28% to $16,393M. Operating margin normalizes from 5.18% in FY2026 to 9.20% in FY2027 and reaches 13.50% at the forecast horizon. Diluted EPS expands from trough GAAP $0.50 to $3.32 in FY2027 and $3.91 in FY2028. Discounted at an 8.46% WACC and 9.81% cost of equity, the fundamental composite fair value resolves to Fair value $51.63.
Upside optionality materializes if Hainan and Asian travel retail channels restock faster than expected, accelerating China revenue above historical baseline trends while M·A·C and prestige skincare drive mid-single-digit growth in the US. In this scenario, fixed SG&A leverage accelerates operating margin expansion by FY2028, pushing diluted EPS toward the high end of consensus ($4.30) and generating robust annual free cash flow, supporting valuation toward Potential value $69.17.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.8% | $55.8 | $57.0 | $58.2 | $59.6 | $61.1 |
| 9.3% | $52.7 | $53.7 | $54.7 | $55.8 | $57.0 |
| 9.8% | $50.0 | $50.8 | $51.6 | $52.6 | $53.6 |
| 10.3% | $47.5 | $48.2 | $48.9 | $49.7 | $50.6 |
| 10.8% | $45.4 | $45.9 | $46.6 | $47.2 | $48.0 |
Upcoming earnings date and setup when available.
매월 발행된 리서치 판이 부여한 등급입니다. 등급은 분석 시점의 가격을 공정 가치와 비교한 것이며, 판단이 맞았는지에 대한 기록이 아닙니다.
| 연도 | 1월 | 2월 | 3월 | 4월 | 5월 | 6월 | 7월 | 8월 | 9월 | 10월 | 11월 | 12월 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |